Colorectal cancer, which affects the colon or rectum, has traditionally been associated with older adults, typically those in their 60s or 70s. This association is well-founded, as the disease has predominantly affected older populations for decades.
However, recent trends are shifting in ways that concern researchers and clinicians. In high-income countries, colorectal cancer rates among adults younger than 50 are rising consistently each year across both sexes, while rates in older adults are declining.
A landmark study published in the European Journal of Cancer (2026) that analyzed data from Switzerland between 1980 and 2021 provides substantial new evidence supporting this trend. Utilizing data from over 96,400 colorectal cancer patients across 42 years, this study represents the first comprehensive nationwide analysis of early-onset colorectal cancer (EOCRC) in Switzerland. The findings are significant and have implications that extend beyond Switzerland.
Two Opposite Trends at the Same Time
The headline finding is a striking divergence. In Switzerland, colorectal cancer rates among adults 50 and older have declined since the mid-2000s, a direct result of widespread screening programs that detect and remove precancerous growths before they become cancer. In men aged 50–74, rates fell by 2.7% per year from 2007 onward. In the oldest adults (75+), the decline was even steeper.
This decline represents a significant public health achievement, demonstrating the effectiveness of screening programs.
In contrast, adults under 50 have experienced a steady increase in incidence, rising by approximately 0.46% per year in men and 0.49% per year in women, with no indication of stabilization throughout the study period from 1980 to 2021. Young adults are now developing colorectal cancer at higher rates than previous generations at the same age, and this disparity continues to grow.
By 2021, individuals under 50 comprised 6.1% of all colorectal cancer cases in Switzerland, an increase from previous decades and amounting to nearly 6,000 patients over the study period.
Who Is Being Affected and Where
The specific type of cancer contributing to the increase among young adults is notable. The rise is primarily driven by rectal cancer, which affects the final section of the large intestine. Among men under 50, rectal cancer incidence increased by approximately 0.84% per year, while in young women, the rate rose by 1.43% per year from 1988 onward.
In young women specifically, another trend emerged: a significant rise in proximal colon cancer tumors in the upper (right) portion of the colon, including the cecum and ascending colon. This particular pattern is notable because proximal colon cancers are generally harder to detect through standard colonoscopy from the left side, and they often present differently from rectal or left-sided colon cancers.
The distribution of cancer location also differs between younger and older patients. Rectal cancers make up nearly 32% of cases in under-50s, compared with only 23% in those 75 and older. Conversely, proximal colon cancers are far more common in older patients (42.7%) than in younger ones (30.5%). This shift in tumor location by age may have implications for how screening and surveillance should be structured for younger adults.
A Harder Diagnosis, Often Too Late
A particularly concerning finding from the study is the stage at which young patients are diagnosed. Cancer stage refers to the extent of disease progression, ranging from Stage I (localized and most treatable) to Stage IV (metastatic and most challenging to treat).
Among Swiss patients under 50 diagnosed between 2010 and 2021, 27.7% were already at Stage IV at diagnosis, meaning the cancer had spread to other organs. By comparison, only 22.1% of 50–74-year-olds and 19.4% of those 75 and older were at Stage IV.
Even more worrying, only 12.6% of young patients were diagnosed at Stage I, the earliest, most treatable stage, compared with 19.4% in the 50–74 group.
The stage at diagnosis has a significant impact on patient outcomes. When colorectal cancer is detected early (Stage I or II), five-year survival rates exceed 90–95%. In contrast, survival rates for Stage IV disease decrease to 22–35%. The tendency for young adults to be diagnosed at later stages is not primarily due to increased tumor aggressiveness, but rather because they are typically excluded from screening programs and their symptoms are frequently overlooked.
In young adults, colorectal cancer is often misdiagnosed as less serious conditions. For example, rectal bleeding may be attributed to hemorrhoids, and abdominal pain may be considered a symptom of irritable bowel syndrome. A recent meta-analysis found that the average interval from initial symptoms to diagnosis in young patients exceeds 4 months, a delay that can be critical to treatment success, particularly at advanced stages.
What’s Causing the Rise?
Researchers don’t have a single explanation. The causes of rising early-onset colorectal cancer are almost certainly multiple and interacting.
Lifestyle factors are the most extensively studied. Increasing obesity rates, physical inactivity, high consumption of ultra-processed foods, red meat, and sugar-sweetened beverages, and rising rates of metabolic syndrome are all implicated. The generations now reaching their 30s and 40s grew up in food environments dramatically different from those of their parents, with more processed food, less physical activity, and greater exposure to endocrine-disrupting compounds.
The gut microbiome has become a significant focus of research. Recent genomic studies have identified Escherichia coli, particularly strains that produce the toxin colibactin, as a potential contributor to colorectal carcinogenesis. A 2025 study in Nature reported a colibactin-associated mutational pattern that is strongly enriched in cancers diagnosed before age 50, suggesting that early-life colonization with these bacteria, potentially through antibiotic use, diet, or other environmental exposures during childhood, may predispose individuals to cancer later in life.
Genetics accounts for a meaningful minority of cases. Genetic testing of young colorectal cancer patients has found inherited risk variants in roughly 15–20% of cases, with Lynch syndrome being the most common. The Swiss researchers note that many of these carriers would have been missed under conventional clinical criteria, supporting a broader push for systematic genetic testing in younger patients.
What This Means for Screening Policy
The primary policy implication of this research concerns the recommended age for screening. Current Swiss guidelines, similar to those in most European countries, advise initiating colorectal cancer screening at age 50. Adults under 50 are generally excluded from routine screening unless they possess specific risk factors, such as a family history of the disease.
The authors of the Swiss study advocate for revising these guidelines. The United States has already implemented such changes; in 2021, the U.S. Preventive Services Task Force reduced the recommended screening age from 50 to 45 years for average-risk adults, a decision informed by data similar to what is now available in Switzerland.
The researchers also emphasize the need for increased symptom awareness among both the public and healthcare providers. When individuals in their 30s or 40s present with rectal bleeding, unexplained anemia, or persistent changes in abdominal function, colorectal cancer should be considered as a potential diagnosis. Delays in diagnosis contribute to poorer outcomes.
The Survival Picture: Progress, But Unevenly Distributed
The study’s survival data provide encouraging findings. Five-year survival rates have improved across all age groups over recent decades. For young patients diagnosed at early stages, outcomes are excellent and comparable to those of older adults at the same stage. Stage I disease in individuals under 50 now has a five-year net survival rate exceeding 95%.
However, these improvements are not uniform. Survival gains have been less consistent among younger women, suggesting potential disparities in healthcare access or biological differences that require further investigation. For Stage IV disease, where a substantial proportion of young patients are diagnosed, survival improvements have been modest, underscoring the limitations of current treatments for advanced cancer.
The primary determinant of patient outcomes is the stage at diagnosis. While advances in treatment, surgical techniques, and chemotherapy are important, early detection remains the most critical factor in improving survival.
What You Can Do
Individuals under 50 are not exempt from the risk of colorectal cancer. The following evidence-based recommendations are relevant for this age group:
It is important to recognize warning signs such as persistent rectal bleeding, unexplained changes in bowel habits, unresolved abdominal pain, unintentional weight loss, or unexplained anemia. These symptoms should not be attributed solely to benign conditions, and prompt medical evaluation is recommended.
Awareness of family history is essential. Individuals with a first-degree relative who has had colorectal cancer or precancerous polyps, particularly before age 60, should consult a healthcare provider regarding the need for earlier and more frequent screening.
Lifestyle factors such as diet, physical activity, and body weight are the most modifiable risk factors. Adopting a diet high in fiber and low in processed meats, along with regular exercise, can reduce risk, particularly when these changes are implemented early in life.
The increasing incidence of colorectal cancer in young adults is not inevitable. Reversing this trend will require earlier detection, increased awareness, and acknowledgment that cancer risk is not confined by age, even if current screening programs are.
Reference
Fournier, E., Schaffar, R., Staehelin, K., Rouxel, N., Ris, F., Toso, C., Frossard, J.-L., Rapiti, E., Koessler, T., Wildisen, L., & Meyer, J. (2026). Rising early-onset colorectal cancer in Switzerland despite declining incidence in older adults: A nationwide population-based study, 1980–2021. European Journal of Cancer, 239, 116707. https://doi.org/10.1016/j.ejca.2026.116707